Published in Medical Verdicts and Law Weekly, July 26th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: GlaxoSmithKline (NYSE:GSK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for a DTaP-IPV combination vaccine (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine combined). GlaxoSmithKline is seeking U.S. approval for the new DTaP-IPV pediatric booster vaccine for immunization against diphtheria, tetanus, whooping cough (pertussis), and polio...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.